NO20072830L - Liposomal formel for bortezomib (PS-341) - Google Patents
Liposomal formel for bortezomib (PS-341)Info
- Publication number
- NO20072830L NO20072830L NO20072830A NO20072830A NO20072830L NO 20072830 L NO20072830 L NO 20072830L NO 20072830 A NO20072830 A NO 20072830A NO 20072830 A NO20072830 A NO 20072830A NO 20072830 L NO20072830 L NO 20072830L
- Authority
- NO
- Norway
- Prior art keywords
- liposomes
- bortezomib
- trapped
- boric acid
- liposome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62521604P | 2004-11-05 | 2004-11-05 | |
PCT/US2005/039972 WO2006052733A1 (en) | 2004-11-05 | 2005-11-04 | Liposomal formulation of bortezomib (ps-341) |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20072830L true NO20072830L (no) | 2007-07-24 |
Family
ID=35947260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20072830A NO20072830L (no) | 2004-11-05 | 2007-06-04 | Liposomal formel for bortezomib (PS-341) |
Country Status (21)
Country | Link |
---|---|
US (2) | US20060153907A1 (ru) |
EP (2) | EP1807052A1 (ru) |
JP (2) | JP2008519040A (ru) |
KR (2) | KR20070085644A (ru) |
CN (2) | CN101094648A (ru) |
AR (1) | AR051759A1 (ru) |
AU (2) | AU2005304881A1 (ru) |
BR (2) | BRPI0517061A (ru) |
CA (2) | CA2586354A1 (ru) |
CR (1) | CR9168A (ru) |
EA (1) | EA200701005A1 (ru) |
IL (1) | IL182967A0 (ru) |
MX (2) | MX2007005499A (ru) |
NI (1) | NI200700120A (ru) |
NO (1) | NO20072830L (ru) |
NZ (2) | NZ554951A (ru) |
PE (1) | PE20061135A1 (ru) |
TW (1) | TW200618820A (ru) |
UY (1) | UY29191A1 (ru) |
WO (2) | WO2006052734A1 (ru) |
ZA (1) | ZA200705017B (ru) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1932517A3 (en) * | 2006-12-11 | 2008-07-16 | Universiteit Utrecht Holding B.V. | Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof |
WO2009047639A2 (en) * | 2007-07-23 | 2009-04-16 | Keimyung University Industry Academic Cooperation Foundation | Epicatechin deficient green tea |
SI2178888T1 (sl) * | 2007-08-06 | 2012-11-30 | Millennium Pharm Inc | Proteasomni inhibitorji |
US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
BRPI0815713A2 (pt) * | 2007-08-21 | 2015-02-10 | Alza Corp | Formulações lipossômicas de compostos de ácido borônico. |
EA201070296A1 (ru) * | 2007-08-21 | 2010-08-30 | Алза Корпорейшн | Липосомные композиции для введения in vivo соединений бороновой кислоты |
SG194349A1 (en) | 2008-06-17 | 2013-11-29 | Millennium Pharm Inc | Boronate ester compounds and pharmaceutical compositions thereof |
KR100918776B1 (ko) * | 2009-04-20 | 2009-09-24 | 계명대학교 산학협력단 | 폴리에틸렌 글리콜과 갈레이트 카테킨을 이용한 혈당상승 억제 조성물 |
KR101661746B1 (ko) | 2008-08-13 | 2016-09-30 | 캘리포니아 인스티튜트 오브 테크놀로지 | 캐리어 나노입자, 그리고 관련된 조성물, 방법 및 시스템 |
RU2529800C2 (ru) * | 2010-03-18 | 2014-09-27 | ИННОФАРМА, Инк. | Стабильные составы бортезомиба |
US8263578B2 (en) | 2010-03-18 | 2012-09-11 | Innopharma, Inc. | Stable bortezomib formulations |
ES2691468T3 (es) | 2010-08-10 | 2018-11-27 | Rempex Pharmaceuticals, Inc. | Derivados de éster del ácido borónico cíclicos y usos terapéuticos de los mismos |
IT1403157B1 (it) | 2010-12-01 | 2013-10-04 | Elbi Int Spa | Macchina lavatrice con rilevazione delle vibrazioni della vasca o camera di lavaggio. |
MX345504B (es) * | 2011-03-02 | 2017-02-02 | Sensulin Llc | Composiciones de vesicula. |
CN102784114B (zh) * | 2011-05-14 | 2016-03-02 | 山东新时代药业有限公司 | 一种硼替佐米冻干粉针及其制备方法 |
AU2013360302C1 (en) | 2012-12-12 | 2019-01-24 | Temple University - Of The Commonwealth System Of Higher Education | Compositions and methods for treatment of cancer |
US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
JP2016509594A (ja) | 2013-01-04 | 2016-03-31 | レンペックス・ファーマシューティカルズ・インコーポレイテッド | ボロン酸誘導体及びその治療的使用 |
US9132097B2 (en) | 2013-03-01 | 2015-09-15 | California Institute Of Technology | Nanoparticles stabilized with nitrophenylboronic acid compositions |
US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
US20160129117A1 (en) | 2013-07-03 | 2016-05-12 | Nippon Kayaku Kabushiki Kaisha | Novel Boronic Acid Compound Preparation |
CN106132970B (zh) * | 2014-02-03 | 2020-09-04 | 俄亥俄州创新基金会 | 硼酸酯和其药物制剂 |
EP3139930A4 (en) | 2014-05-05 | 2018-01-17 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
DK3140310T3 (da) | 2014-05-05 | 2019-10-21 | Rempex Pharmaceuticals Inc | Syntese af boronatsalte og brug deraf |
EP3145936B1 (en) | 2014-05-19 | 2020-09-30 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
JP2017524652A (ja) | 2014-05-20 | 2017-08-31 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤 |
EP3164406A4 (en) * | 2014-07-01 | 2018-04-04 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
WO2016081297A1 (en) | 2014-11-18 | 2016-05-26 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
WO2016149393A1 (en) | 2015-03-17 | 2016-09-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
AU2016256979B2 (en) * | 2015-05-04 | 2021-01-28 | Versantis AG | Method for preparing transmembrane pH-gradient vesicles |
EP3310360B1 (en) * | 2015-06-19 | 2024-03-27 | Beijing Artivila BioPharma Co. Ltd. | Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis |
WO2017003668A1 (en) | 2015-07-01 | 2017-01-05 | California Institute Of Technology | Cationic mucic acid polymer-based delivery systems |
CN104958768A (zh) * | 2015-07-17 | 2015-10-07 | 中国科学院长春应用化学研究所 | 一种葡聚糖-硼替佐米键合药及其制备方法 |
US11135309B2 (en) * | 2015-08-14 | 2021-10-05 | The Regents Of The University Of California | Poly(vinyl alcohol) nanocarriers |
ES2894251T3 (es) | 2016-06-30 | 2022-02-14 | Qpex Biopharma Inc | Derivados de ácido borónico y usos terapéuticos de los mismos |
US10583083B1 (en) * | 2016-08-10 | 2020-03-10 | Verily Life Sciences Llc | ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages |
JP2020500839A (ja) | 2016-10-20 | 2020-01-16 | ファイザー・インク | ペプチドボロン酸またはボロン酸エステル化合物を有する治療用粒子ならびにその作製および使用方法 |
CN111372580A (zh) * | 2017-07-24 | 2020-07-03 | 国邑药品科技股份有限公司 | 包含弱酸药物的脂质体组合物及其用途 |
JP7377545B2 (ja) | 2017-10-11 | 2023-11-10 | キューペックス バイオファーマ, インコーポレイテッド | ボロン酸誘導体およびその合成 |
CN112424209A (zh) | 2018-04-20 | 2021-02-26 | Qpex生物制药有限公司 | 硼酸衍生物及其治疗用途 |
CN110540547A (zh) | 2018-05-28 | 2019-12-06 | 秦艳茹 | 一种肽硼酸酯类化合物的合成与用途 |
CA3099440A1 (en) | 2018-06-13 | 2019-12-19 | California Institute Of Technology | Nanoparticles for crossing the blood brain barrier and methods of treatment using the same |
CN109045272A (zh) * | 2018-08-01 | 2018-12-21 | 厦门市壳聚糖生物科技有限公司 | 一种硼替佐米磷脂复合物及其制备方法与应用 |
EP4041246A4 (en) * | 2019-10-07 | 2023-11-01 | Cornell University | ANTIMICROBIAL AND ANTIVIRAL EFFECTS OF ALKYL-BORONIC ACIDS C2-C7 |
US20240173374A1 (en) * | 2021-02-25 | 2024-05-30 | Ohio State Innovation Foundation | Liposomal formulations of boronic acid containing active agents |
CN112915094A (zh) * | 2021-03-26 | 2021-06-08 | 东南大学 | 一种硼替佐米脂质体制剂的制备方法 |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5736155A (en) * | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
US5077056A (en) * | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
US4885172A (en) * | 1985-06-26 | 1989-12-05 | The Liposome Company, Inc. | Composition for targeting, storing and loading of liposomes |
US5047245A (en) * | 1985-07-26 | 1991-09-10 | The Liposome Company, Inc. | Novel composition for targeting, storing and loading of liposomes |
US5252263A (en) * | 1986-06-16 | 1993-10-12 | The Liposome Company, Inc. | Induction of asymmetry in vesicles |
IL91664A (en) * | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
US6132763A (en) * | 1988-10-20 | 2000-10-17 | Polymasc Pharmaceuticals Plc | Liposomes |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5620689A (en) * | 1989-10-20 | 1997-04-15 | Sequus Pharmaceuuticals, Inc. | Liposomes for treatment of B-cell and T-cell disorders |
DK0555229T3 (da) * | 1990-07-31 | 1996-08-19 | Liposome Co Inc | Akkumulation af aminosyrer og peptider i liposomer |
US5395619A (en) * | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
US6180134B1 (en) * | 1993-03-23 | 2001-01-30 | Sequus Pharmaceuticals, Inc. | Enhanced ciruclation effector composition and method |
US6326353B1 (en) * | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US6214388B1 (en) * | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US5972379A (en) * | 1995-02-14 | 1999-10-26 | Sequus Pharmaceuticals, Inc. | Liposome composition and method for administering a quinolone |
DE69632859T2 (de) * | 1995-04-18 | 2005-07-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Verfahren zur Arzneistoffbehandlung von Liposomen Zusammensetzung |
US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
US6224903B1 (en) * | 1996-10-11 | 2001-05-01 | Sequus Pharmaceuticals, Inc. | Polymer-lipid conjugate for fusion of target membranes |
AU4907897A (en) * | 1996-10-11 | 1998-05-11 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
WO1998017256A1 (en) * | 1996-10-22 | 1998-04-30 | Dmitri Kirpotin | Compound-loaded liposomes and methods for their preparation |
US6831057B2 (en) * | 1997-10-28 | 2004-12-14 | The University Of North Carolina At Chapel Hill | Use of NF-κB inhibition in combination therapy for cancer |
US6051251A (en) * | 1997-11-20 | 2000-04-18 | Alza Corporation | Liposome loading method using a boronic acid compound |
DK1121102T3 (da) * | 1998-09-16 | 2003-08-11 | Alza Corp | Liposomindesluttede topoisomeraseinhibitorer |
ES2255501T3 (es) * | 1999-07-14 | 2006-07-01 | Alza Corporation | Lipopolimeros neutros y composiciones liposomicas que los contienen. |
JP2003514023A (ja) * | 1999-11-19 | 2003-04-15 | トツプジーン・インコーポレイテツド | 抗炎症剤としてのホウ素化合物および複合体 |
US6713446B2 (en) * | 2001-01-25 | 2004-03-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Formulation of boronic acid compounds |
US20060084592A1 (en) * | 2002-09-09 | 2006-04-20 | Trigen Limited | Peptide boronic acid inhibitors |
WO2004043374A2 (en) * | 2002-11-06 | 2004-05-27 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for treating cancer using proteasome inhibitors |
-
2005
- 2005-10-25 TW TW094137236A patent/TW200618820A/zh unknown
- 2005-11-02 PE PE2005001284A patent/PE20061135A1/es not_active Application Discontinuation
- 2005-11-04 BR BRPI0517061-3A patent/BRPI0517061A/pt not_active IP Right Cessation
- 2005-11-04 MX MX2007005499A patent/MX2007005499A/es unknown
- 2005-11-04 KR KR1020077012434A patent/KR20070085644A/ko not_active Application Discontinuation
- 2005-11-04 WO PCT/US2005/039973 patent/WO2006052734A1/en active Application Filing
- 2005-11-04 AR ARP050104638A patent/AR051759A1/es unknown
- 2005-11-04 JP JP2007540070A patent/JP2008519040A/ja not_active Withdrawn
- 2005-11-04 EA EA200701005A patent/EA200701005A1/ru unknown
- 2005-11-04 NZ NZ554951A patent/NZ554951A/en not_active IP Right Cessation
- 2005-11-04 EP EP05821699A patent/EP1807052A1/en not_active Withdrawn
- 2005-11-04 CA CA002586354A patent/CA2586354A1/en not_active Abandoned
- 2005-11-04 US US11/267,794 patent/US20060153907A1/en not_active Abandoned
- 2005-11-04 CN CNA2005800457552A patent/CN101094648A/zh active Pending
- 2005-11-04 EP EP05824137A patent/EP1807053A1/en not_active Withdrawn
- 2005-11-04 KR KR1020077012432A patent/KR20070085642A/ko not_active Application Discontinuation
- 2005-11-04 MX MX2007005497A patent/MX2007005497A/es unknown
- 2005-11-04 CA CA002586348A patent/CA2586348A1/en not_active Abandoned
- 2005-11-04 US US11/267,076 patent/US20060159736A1/en not_active Abandoned
- 2005-11-04 UY UY29191A patent/UY29191A1/es unknown
- 2005-11-04 BR BRPI0517668-9A patent/BRPI0517668A/pt not_active IP Right Cessation
- 2005-11-04 CN CNA2005800457618A patent/CN101094649A/zh active Pending
- 2005-11-04 WO PCT/US2005/039972 patent/WO2006052733A1/en active Application Filing
- 2005-11-04 AU AU2005304881A patent/AU2005304881A1/en not_active Abandoned
- 2005-11-04 JP JP2007540071A patent/JP2008519041A/ja not_active Withdrawn
- 2005-11-04 AU AU2005304880A patent/AU2005304880A1/en not_active Abandoned
- 2005-11-04 NZ NZ554950A patent/NZ554950A/en not_active IP Right Cessation
-
2007
- 2007-05-03 IL IL182967A patent/IL182967A0/en unknown
- 2007-05-04 NI NI200700120A patent/NI200700120A/es unknown
- 2007-06-04 ZA ZA200705017A patent/ZA200705017B/xx unknown
- 2007-06-04 NO NO20072830A patent/NO20072830L/no not_active Application Discontinuation
- 2007-06-05 CR CR9168A patent/CR9168A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2008519040A (ja) | 2008-06-05 |
EA200701005A1 (ru) | 2007-10-26 |
WO2006052733A1 (en) | 2006-05-18 |
EP1807052A1 (en) | 2007-07-18 |
IL182967A0 (en) | 2007-08-19 |
CR9168A (es) | 2008-11-24 |
MX2007005499A (es) | 2007-09-21 |
PE20061135A1 (es) | 2006-10-20 |
AU2005304880A1 (en) | 2006-05-18 |
UY29191A1 (es) | 2006-01-31 |
CN101094648A (zh) | 2007-12-26 |
WO2006052734A1 (en) | 2006-05-18 |
NZ554950A (en) | 2010-12-24 |
BRPI0517061A (pt) | 2008-09-30 |
TW200618820A (en) | 2006-06-16 |
US20060153907A1 (en) | 2006-07-13 |
NZ554951A (en) | 2010-12-24 |
CA2586348A1 (en) | 2006-05-18 |
CN101094649A (zh) | 2007-12-26 |
BRPI0517668A (pt) | 2008-10-14 |
KR20070085644A (ko) | 2007-08-27 |
EP1807053A1 (en) | 2007-07-18 |
AR051759A1 (es) | 2007-02-07 |
KR20070085642A (ko) | 2007-08-27 |
NI200700120A (es) | 2008-05-15 |
US20060159736A1 (en) | 2006-07-20 |
JP2008519041A (ja) | 2008-06-05 |
AU2005304881A1 (en) | 2006-05-18 |
CA2586354A1 (en) | 2006-05-18 |
MX2007005497A (es) | 2007-09-21 |
ZA200705017B (en) | 2008-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20072830L (no) | Liposomal formel for bortezomib (PS-341) | |
CR20110324A (es) | ANTICUERPO ANTI-cMET NOVEDOSO | |
SE0301882D0 (sv) | New use I | |
SE0301886D0 (sv) | New use V | |
UA89035C2 (ru) | Эфиры гидроксамовых кислот и их фармацевтическое применение | |
WO2008066887A3 (en) | Small molecule inhibitors of bcl6 | |
NI201000030A (es) | Formulaciones de liposomas de compuestos de ácidos borónico | |
EP1829863A4 (en) | ARYLALCANOIC ACID DERIVATIVE | |
WO2009018219A3 (en) | Methods and compositions for modulating rad51 and homologous recombination | |
PE20060425A1 (es) | Formulacion de tableta revestida que comprende saxagliptina | |
WO2010009892A8 (en) | Compositions for the treatment of pain and/or inflamation | |
SG148178A1 (en) | Indozolone derivatives as 11b-hsd1 inhibitors | |
RU2012130405A (ru) | Хальконы в качестве усилителей антимикробных средств | |
NI200800175A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de abuso y adicción de sustancias. | |
MY158428A (en) | Topical composition for the treatment of actinic keratosis | |
BR0314450A (pt) | Sais de ácido borÈnico com adição de uma base farmaceuticamente aceitável, formulação farmacêutica, e uso dos referidos sais para preparar uma formulação farmacêutica | |
WO2005123192A3 (en) | Improving pain treatment with strontium combinations | |
MX335945B (es) | Composicion antifungica novedosa. | |
CY1108069T1 (el) | Φαρμακευτικη συνθεση σε μορφη υδρογελης για διαδερμικη χορηγηση δραστικων ουσιων | |
WO2010009369A3 (en) | Methods and materials for the treatment of acne | |
MXPA04009421A (es) | Compuestos de tiazol-2-ilimina como inhibidores de la pde-7. | |
SE0301883D0 (sv) | New use II | |
UY26648A1 (es) | Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada | |
SE0301885D0 (sv) | New use IV | |
IL164735A0 (en) | Annelated pyrrole compounds as proton pump inhibitors for treating ulcer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |